Recruiting
HER2 positive endometrial cancer
RecruitingStudy of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer
Registered drugNo placebo
Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer
Registered drugNo placebo
- Disease:HER2 positive endometrial cancer
- Substances:CarboplatinCisplatin+3
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Daiichi Sankyo Inc.



